- Home
- GAM vs AUPH Comparison
GAM vs AUPH Comparison
Compare GAM & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAM
- AUPH
- Stock Information
- Founded
- GAM 1927
- AUPH 1993
- Country
- GAM United States
- AUPH Canada
- Employees
- GAM N/A
- AUPH N/A
- Industry
- GAM Investment Managers
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- GAM Finance
- AUPH Health Care
- Exchange
- GAM Nasdaq
- AUPH Nasdaq
- Market Cap
- GAM 1.3B
- AUPH 1.0B
- IPO Year
- GAM N/A
- AUPH 1999
- Fundamental
- Price
- GAM $50.32
- AUPH $8.86
- Analyst Decision
- GAM
- AUPH Strong Buy
- Analyst Count
- GAM 0
- AUPH 3
- Target Price
- GAM N/A
- AUPH $10.33
- AVG Volume (30 Days)
- GAM 20.1K
- AUPH 1.5M
- Earning Date
- GAM 01-01-0001
- AUPH 11-07-2024
- Dividend Yield
- GAM 5.74%
- AUPH N/A
- EPS Growth
- GAM N/A
- AUPH N/A
- EPS
- GAM 11.67
- AUPH N/A
- Revenue
- GAM N/A
- AUPH $220,361,000.00
- Revenue This Year
- GAM N/A
- AUPH $36.52
- Revenue Next Year
- GAM N/A
- AUPH $19.02
- P/E Ratio
- GAM $3.95
- AUPH N/A
- Revenue Growth
- GAM N/A
- AUPH 38.72
- 52 Week Low
- GAM $37.32
- AUPH $4.71
- 52 Week High
- GAM $46.48
- AUPH $9.74
- Technical
- Relative Strength Index (RSI)
- GAM 33.33
- AUPH 72.92
- Support Level
- GAM $49.34
- AUPH $7.87
- Resistance Level
- GAM $55.05
- AUPH $8.70
- Average True Range (ATR)
- GAM 0.78
- AUPH 0.39
- MACD
- GAM -0.52
- AUPH 0.06
- Stochastic Oscillator
- GAM 17.15
- AUPH 90.77
About GAM General American Investors Inc.
General American Investors Company Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.